Clinical trials: Detrusor, Overactive
Detrusor Hyperreflexia
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
- Trial name
- NCT00224029
- Testing
- Oxybutynin transdermal system
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder
Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Overactive bladder (OAB) is a bothered symptom syndrome. Traditional medication for OAB is antimuscarinic agent. However, adverse events such as dry mouth, constipation, blurred vision, and dizziness may prohibit patient to take…
- Trial name
- NCT01167257
- Testing
- Liposome encapsulated botulinum toxin A, Normal saline instillation
- Where
- Taiwan
- Volunteers
- 62 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Neurogenic Detrusor Overactivity
Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury
Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Rec 0/0438 in subjects with neurogenic detrusor overactivity due to spinal cord injury
- Trial name
- NCT03482037
- Testing
- Rec 0/0438 1 mg or Rec 0/0438 2 mg
- Where
- 9 sites in Czechia, France and 2 more
- Volunteers
- 42 people
- Sponsor
- RECORDATI GROUP
Overactive Bladder, Detrusor Overactivity
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
The purpose of this study is to assess if the study drug, Vardenafil (approved by Health Authorities is available on the market for treatment of erectile dysfunction) has an effect on bladder function and micturition frequency.
- Trial name
- NCT00478881
- Testing
- Vardenafil HCl (Levitra, BAY38-9456)
- Where
- 55 sites in Belgium, Canada and 11 more
- Volunteers
- 397 people
- Sponsor
- Bayer
Overactive Bladder
Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
This study evaluated the outcomes of women with detrusor overactivity treated with combined pharmacotherapy to identify risk factors for treatment failure.
- Trial name
- NCT07337252
- Testing
- Combined pharmacotherapy
- Where
- Taiwan
- Volunteers
- 61 people
- Sponsor
- Mackay Memorial Hospital
Detrusor Overactivity
UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation
The purpose of this study is to find a noninvasive test to help physicians diagnose detrusor overactivity (DO), to use this urine test to help diagnose bladder problems, determine if treatments are working, and determine if…
- Trial name
- NCT01850706
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive…
- Trial name
- NCT02590250
- Testing
- botulinum toxin Type A
- Where
- 12 sites in India
- Volunteers
- 250 people
- Sponsor
- Allergan
Urinary Incontinence, Multiple Sclerosis
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
- Conditions
- Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
- Trial name
- NCT01600716
- Testing
- OnabotulinumtoxinA
- Where
- 10 sites in United States, Belgium and 6 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Urologic Diseases, Overactive Bladder Syndrome
Trigonal vs Non Trigonal Botox Injection in OAB.
The investigators attend to conduct a prospective randomized study to assess safety and efficacy of trigonal-involved vs. trigonal-sparing botox injection technique, quality of life measurement and post-injection anticholinergics…
- Conditions
- Urologic Diseases, Overactive Bladder Syndrome, Quality of Life, Anticholinergic Syndrome
- Trial name
- NCT03533062
- Testing
- botulinum toxin A
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Spinal Cord Injury, Neurogenic Detrusor Overactivity
Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity
This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for…
- Trial name
- NCT00800462
- Testing
- Oxybutynin Cl, Trospium Cl, Darifenacin Hydrogen Bromide (HBr)
- Where
- 2 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Toronto Rehabilitation Institute
Urinary Incontinence, Overactive Bladder Syndrome
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with…
- Conditions
- Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
- Trial name
- NCT05878951
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Northwestern University
Urinary Incontinence, Urinary Bladder, Neurogenic
Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
Incontinence associates with military service and post-traumatic stress disorder in both male and female Veterans. Neurogenic detrusor overactivity (NDO) is caused by spinal cord injury or disorder, or peripheral…
- Trial name
- NCT05141487
- Testing
- UroMonitor, ASCU
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- VA Office of Research and Development
Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.
- Conditions
- Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic, Bladder Disorder, Neurogenic, Urinary Bladder Disorder, Neurogenic
- Trial name
- NCT01530620
- Testing
- Propiverine hydrochloride ER (extended release), Propiverine hydrochloride IR (immediate release)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- APOGEPHA Arzneimittel GmbH
Detrusor Underactivity, Overactive Bladder
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.
- Trial name
- NCT03175029
- Testing
- TAC-302
- Where
- Japan
- Volunteers
- 195 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Neurogenic Urinary Bladder, Neurogenic Bladder Disorder
Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions
This study will assess the safety, tolerability and efficacy of SAF312 in patients with overactive bladder disease due to spinal cord lesions.
- Conditions
- Neurogenic Urinary Bladder, Neurogenic Bladder Disorder, Neurogenic Dysfunction of the Urinary Bladder, Neurogenic Bladder, Uninhibited
- Trial name
- NCT01598103
- Testing
- SAF312
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Bladder, Neurogenic, Neuropathic Bladder
Detrusor Contraction During the Ice-water-test
In this randomized, double-blind clinical trial including patients with a neurogenic lower urinary tract dysfunction undergoing urodynamic investigation at the Spinal Cord Injury Center, Balgrist University Hospital, Zürich, we…
- Trial name
- NCT01773213
- Testing
- Ice-water-test
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Balgrist University Hospital
Neurogenic Detrusor Overactivity
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
People with neurogenic detrusor overactivity (NDO) have poor bladder control because of how their nerves to the bladder are wired. This can cause high pressure in the bladder, causing it to leak urine by accident (incontinence).
- Trial name
- NCT05621616
- Testing
- mirabegron
- Where
- 3 sites in Philippines, Poland
- Volunteers
- 7 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder (OAB), Detrusor Overactivity
Bladder Training With or Without Biofeedback-Assisted Pelvic Floor Muscle Training for Women With Wet Overactive Bladder
Overactive bladder causes a sudden and difficult-to-control need to urinate and may be accompanied by urine leakage. Bladder training is commonly used as a first-line treatment.
- Conditions
- Overactive Bladder (OAB), Detrusor Overactivity, Urgency Urinary Incontinence
- Trial name
- NCT07728747
- Testing
- Bladder Training, EMG Biofeedback-Assisted Pelvic Floor Muscle Training
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Gaziantep Islam Science and Technology University
Spinal Cord Injury, Neurogenic Detrusor Overactivity
Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?
Spinal cord injury (SCI) almost always affects bladder function as well. As a result of this bladder dysfunction, individuals with SCI have to undergo regular invasive examination of their bladder function (urodynamic…
- Conditions
- Spinal Cord Injury, Neurogenic Detrusor Overactivity, Neurogenic Lower Urinary Tract Dysfunction
- Trial name
- NCT02138149
- Where
- Switzerland
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Swiss Paraplegic Research, Nottwil
Overactive Bladder Syndrome
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Idiopathic Detrusor Overactivity.
- Trial name
- NCT00335660
- Testing
- AV608
- Where
- 13 sites in Netherlands, United Kingdom
- Volunteers
- 62 people
- Sponsor
- Avera Pharmaceuticals